home / stock / cybn:cc / cybn:cc news

CYBN:CC News and Press, CYBIN INC. From 10/23/23

Stock Information
Company Name: CYBIN INC.
Stock Symbol: CYBN:CC
Market: AQNC
Menu
CYBN:CC CYBN:CC Quote CYBN:CC Short CYBN:CC News CYBN:CC Articles CYBN:CC Message Board
Get CYBN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CYBN:CC - Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023. - Combined portfolios create the industry’s largest, most adv...
CYBN:CC - Small Pharma Obtains Final Order Approving Arrangement

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharma...

CYBN:CC - InvestorNewsBreaks - Cybin Inc.'s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the results of its annual and special meeting of shareholders, which was h...

CYBN:CC - Cybin Announces Results of Annual and Special Meeting of Shareholders

Cybin Inc. (NYSE AMERICAN:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce t...
CYBN:CC - InvestorNewsBreaks - Cybin Inc.'s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be presenting at the Neuropsychiatric Drug Development Summit, slated for Oct. 11...

CYBN:CC - Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

- Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT 2A receptor full agonist with therapeutic potential” - - Highlights preclinical work done to support selection of a development candidate for the Company’s phenethylamine program...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has announced that its CEO Doug Drysdale will present at the Jefferies Inaugural Biotech CNS/Ne...
CYBN:CC - Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce t...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing of the final cohort for its phase 2 CYB003 study. According to the an...

CYBN:CC - Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

- Topline efficacy data expected in Q4 2023 - - Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage ...
Previous 10 Next 10